Investigational drug · Phase 3
MR-107A-02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Pain, Post Operative Pain, Pain.
Phase 3Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "MR-107A-02"
First trial start
2023
Dec 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MR-107A-02", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Pain
- Post Operative Pain
- Pain
Approved drugs for the same conditions: Acute pain · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "MR-107A-02" as an intervention, largest first.
- Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following HerniorrhaphyPivotal-lookingCompleted
Viatris Specialty LLCIndustry
NCT06215859 · 579 participants · Start Dec 29, 2023 · Primary completion Jan 31, 2025
Drug: MR-107A-02; Tramadol and 1 more · For: Acute Pain; Post Operative Pain; Pain
Sites: Sheffield, Alabama; Phoenix, Arizona; Anaheim, California · 18 sites in all
- Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following BunionectomyPivotal-lookingCompleted
Viatris Specialty LLCIndustry
NCT06215820 · 410 participants · Start Dec 29, 2023 · Primary completion Aug 24, 2024
Drug: MR-107A-02; Tramadol and 1 more · For: Acute Pain; Post Operative Pain; Pain
Sites: Sheffield, Alabama; Phoenix, Arizona; Anaheim, California · 15 sites in all
- Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.Pivotal-lookingCompleted
Mylan Specialty, LPIndustry
NCT05317312 · 111 participants · Start Mar 31, 2022 · Primary completion Jun 15, 2022
Drug: MR-107A-02; Placebo · For: Acute Pain; Post Operative Pain; Pain
Sites: Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- A randomized, double-blind, placebo-controlled, parallel group, dose-response study of MR-107A-02 in the treatment of post-surgical dental pain.
Bertoch TM, Grisham S, Vogt S, et al. · Pain Med 2026
- MR-107A-02 in Acute Postoperative Pain Management Following Bunionectomy: Results from a Multicenter, Placebo- and Active-Controlled, Phase 3 Trial.
Bertoch T, McCoun JC, Gottlieb I, et al. · Pain Ther 2026
- Comparison of the pharmacokinetics of MR-107A-02, a novel fast-absorbing formulation of meloxicam, versus standard meloxicam reference: a phase I study.
Hummel MA, Shaw A, Liu MS, et al. · Expert Opin Drug Deliv 2025
Also in development for Acute Pain
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- matched to VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
- VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
- GRT7040Phase 21 trial
Grünenthal GmbH · Acute Pain, Bunionectomy
- LY4515100Phase 21 trial
Eli Lilly · Acute Pain, Molar, Molar, Third
- SRP-001Phase 21 trial
South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.